{"entity":{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of YH32364 in advanced solid tumours, run by Yuhan Corporation, now recruiting.","summary":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors is a phase 1/2 interventional study registered as NCT06975410 by Yuhan Corporation, with 80 participants planned, started 2025-06-12 and due to reach its primary completion in 2027-06. Interventions recorded: YH32364.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06975410","url":"https://clinicaltrials.gov/study/NCT06975410"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["yuhan"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06975410","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Yuhan Corporation","started":"2025-06-12","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06975410/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/"}]}}